Sejahteraraya Anugrahjaya Tbk PT
IDX:SRAJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (29.8), the stock would be worth Rp-1 148.54 (108% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -394.1 | Rp15 175 |
0%
|
| Industry Average | 29.8 | Rp-1 148.54 |
-108%
|
| Country Average | 9.6 | Rp-368.59 |
-102%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| ID |
S
|
Sejahteraraya Anugrahjaya Tbk PT
IDX:SRAJ
|
185.7T IDR | -394.1 | -933.3 | |
| US |
|
HCA Healthcare Inc
NYSE:HCA
|
97.2B USD | 17.1 | 14.3 | |
| SA |
|
Dr Sulaiman Al-Habib Medical Services Group Co
SAU:4013
|
98B SAR | 250.4 | 40.8 | |
| ZA |
N
|
Netcare Ltd
JSE:NTC
|
23.2B ZAR | 40.7 | 13.9 | |
| MY |
I
|
IHH Healthcare Bhd
KLSE:IHH
|
77.8B MYR | 41.5 | 37.1 | |
| ZA |
L
|
Life Healthcare Group Holdings Ltd
JSE:LHC
|
17.5B ZAR | 5.4 | 4.5 | |
| BR |
|
Rede D'Or Sao Luiz SA
BOVESPA:RDOR3
|
84.8B BRL | -33 | 17.9 | |
| US |
|
Tenet Healthcare Corp
NYSE:THC
|
15.7B USD | 10.2 | 11.2 | |
| CN |
A
|
Aier Eye Hospital Group Co Ltd
SZSE:300015
|
102.1B CNY | 26.5 | 30.3 | |
| IN |
|
Apollo Hospitals Enterprise Ltd
NSE:APOLLOHOSP
|
1.1T INR | 108.2 | 60.6 | |
| US |
|
Ensign Group Inc
NASDAQ:ENSG
|
10.8B USD | 27.7 | 31.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 5.7 |
| Median | 9.6 |
| 70th Percentile | 18 |
| Max | 1 364 898.3 |
Other Multiples
Sejahteraraya Anugrahjaya Tbk PT
Glance View
Sejahteraraya Anugrahjaya Tbk PT, widely recognized as a pivotal player in Indonesia’s healthcare sector, stands out for its commitment to providing high-quality medical services through its premier brand, Mayapada Hospital. The company operates an expanding network of hospitals strategically positioned to serve Indonesia's bustling metropolitan areas, catering to a diverse demographic in need of trusted and reliable healthcare. Each facility under Sejahteraraya Anugrahjaya is equipped with advanced medical technology and accredited healthcare professionals, which not only attract domestic patients but also garner interest from international clientele seeking specialized treatment. This emphasis on quality and accessibility forms the backbone of its business model, while diversifying services ensures both steady revenue flow and resilience against economic fluctuations. By focusing on a broad range of healthcare services—from general consultations and diagnostics to specialized medical treatments and emergency care—Sejahteraraya Anugrahjaya Tbk PT secures various revenue streams. The institution capitalizes on Indonesia's growing demand for healthcare services driven by its burgeoning middle class and increasing health consciousness among the population. Insurance partnerships and direct patient payments constitute primary income channels, further enhanced by healthcare innovations and expansions. Through continuous investments in building state-of-the-art facilities and fostering strategic alliances, the company adeptly navigates the competitive healthcare landscape, ensuring sustainable growth and setting a benchmark for medical excellence in the region.